A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants with Adverse Events (AE)s

  Measured over: Up to Approximately 130 Months

• Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)

  Measured over: Up to Approximately 8 weeks

• Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)

  Measured over: Up to Approximately 8 Weeks

• Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)

  Measured over: Up to Approximately 8 Weeks

• Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMM

  Measured over: Up to Approximately 8 Weeks

• Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MM

  Measured over: Up to Approximately 8 Weeks

• Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MM

  Measured over: Up to Approximately 8 Weeks

• Substudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MM

  Measured over: Up to Approximately 8 Weeks

• Substudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MM

  Measured over: Up to Approximately 8 Weeks

Changes Tremor has spotted